

Cite this: *Anal. Methods*, 2023, 15, 1797

## Development of a sensitive biochemical assay for the detection of tofacitinib adherence

Stephanie Church,<sup>a</sup> Kimme L. Hyrich,<sup>bc</sup> Kayode Ogungbenro,<sup>d</sup> Richard D. Unwin,<sup>de</sup> Anne Barton<sup>cf</sup> and James Bluett<sup>id\*cf</sup>

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease. Tofacitinib is a Janus Kinase inhibitor licensed for the treatment of RA that, unlike biologic anti-rheumatic drugs, is administered orally, but studies of long-term treatment adherence rates are lacking. The measurement of adherence, however, is challenging and there is currently no gold standard test for adherence. Here, we developed a novel HPLC MS/MS assay for the quantification of tofacitinib. The assay demonstrated a LLOQ for tofacitinib of 0.1 ng ml<sup>-1</sup>, within run accuracy was 81–85% at LLOQ and 91–107% at all other levels. To investigate the ability of the assay to detect adherence, tofacitinib was measured in a random selection of serum samples ( $n = 10$ ) of tofacitinib treated RA patients who self-reported adherent behaviour. The assay measured tofacitinib in all samples above the LLOQ demonstrating the potential of the assay to sensitively measure biochemical adherence in real-world patient samples. This method for detection of adherence has the potential to be a more objective measure that could be used in the future in the clinic but will require further studies to explore factors that may influence measurement of drug levels, such as clinical characteristics of patients.

Received 2nd November 2022

Accepted 3rd March 2023

DOI: 10.1039/d2ay01800d

rsc.li/methods

### Introduction

Tofacitinib is a Janus Kinase (JAK) inhibitor in tablet form that selectively inhibits the JAK1/3 tyrosine kinases available in 5 mg twice daily or once-daily 11 mg modified-release dosing. The JAK tyrosine kinases are intracellular signalling proteins, responsible for activating downstream Signal Transducer and Activator of Transcription (STAT) proteins that regulate gene transcription. JAK activation relies upon binding of cytokines to the type I and type II cytokine receptors, including pro-inflammatory cytokines such as type I interferons and IL-6.<sup>1</sup> Selective inhibition of the JAK tyrosine kinases is used to treat several chronic inflammatory diseases. In the United Kingdom

(UK), tofacitinib is licensed for the treatment of rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colitis.

In RA, a chronic inflammatory arthritis, early effective treatment has been shown to reduce joint erosions and disability.<sup>2</sup> Patients in the UK with severe, active RA that has failed to respond to conventional anti-rheumatic drug treatments are eligible for the second-line more effective biologic (b) or targeted synthetic (ts) disease modifying anti-rheumatic drugs (DMARDs), such as tofacitinib. Second-line therapy response is not, however, universal and up to 27% of RA patients do not take their subcutaneous bDMARD as prescribed resulting in significantly reduced response.<sup>3</sup> One of the most common side effects of subcutaneously administered bDMARDs is injection site reactions and injection site pain is a significant predictor of non-adherence.<sup>4</sup> Oral administration offers a major potential benefit to patients, removing the risk of injection site reactions. Frequency and route of administration may affect patients' adherence and patients prefer an oral DMARD.<sup>5</sup> Oral tofacitinib has been shown to be at least as effective as the traditional subcutaneous bDMARD for treating RA<sup>6–8</sup> but it is unclear whether adherence is higher.

Previous research utilising prescription claims has revealed no difference between adherence to tofacitinib and subcutaneous bDMARDs.<sup>9–11</sup> However, the use of indirect measures such as pharmacy refill data can be inaccurate indicating a need for a more accurate and objective adherence measurement. Tofacitinib levels *in vivo* can be measured using High Performance Liquid Chromatography Selected Reaction Monitoring Mass

<sup>a</sup>Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, Core Technology Facility, The University of Manchester, Grafton Street, Manchester, M13 9NT, UK

<sup>b</sup>Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK

<sup>c</sup>NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, UK. E-mail: james.bluett@manchester.ac.uk

<sup>d</sup>Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK

<sup>e</sup>Stoller Biomarker Discovery Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, CityLabs 1.0 (3rd Floor), Nelson Street, Manchester, M13 9NQ, UK

<sup>f</sup>Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, The University of Manchester, UK



Spectrometry (HPLC-SRM-MS). The pharmacokinetic profile of tofacitinib using a simulated physiologically-based pharmacokinetic (PBPK) model demonstrates that a lower limit of quantification (LLOQ) of 0.1 ng ml<sup>-1</sup> is sufficient for the detection of adherence following 5 mg twice daily administration.<sup>12</sup>

Without an objective direct measure of adherence, it remains uncertain whether the patient benefits of oral over subcutaneous DMARDs is associated with improved adherence. The aim of the present study is to, therefore, develop a sensitive novel HPLC-SRM-MS tofacitinib assay using the EMA guidelines as a benchmark<sup>13</sup> with exploration of the ability of the assay to detect adherence in patient samples.

## Experimental

### Materials and methods

**Reagents and chemicals.** Tofacitinib citrate and deuterium-labelled tofacitinib (tofacitinib-d3) were purchased from Cayman Chemical (Michigan, USA). LC-MS grade acetonitrile (ACN), water, pooled human serum and formic acid were purchased from Merck (Dorset, United Kingdom).

**Preparation of standards and samples.** Human serum for method development was obtained from healthy volunteers recruited to the collection of blood and urine samples from volunteers for the development of analytical methods study (UREC 12346) and the National Repository Study (REC 99/8/84) following informed consent.

Stock solutions of tofacitinib and tofacitinib-d3 were prepared in water at 100 µg ml<sup>-1</sup> for tofacitinib and 500 µg ml<sup>-1</sup> for tofacitinib-d3 and stored at -80 °C. Working solutions were prepared freshly for each batch of samples. Samples were prepared in 2 ml safe-lock tubes (Eppendorf®). Samples were spiked with tofacitinib and tofacitinib-d3 to give a final concentration of 50 ng ml<sup>-1</sup> tofacitinib-d3 and final concentrations of tofacitinib at 0.1 ng ml<sup>-1</sup>, 0.25 ng ml<sup>-1</sup>, 0.5 ng ml<sup>-1</sup>, 1 ng ml<sup>-1</sup>, 2.5 ng ml<sup>-1</sup>, 5 ng ml<sup>-1</sup>, 10 ng ml<sup>-1</sup>, 50 ng ml<sup>-1</sup> and 100 ng ml<sup>-1</sup>. Protein precipitation was performed by the addition of 200 µl ACN to 50 µl sample, samples were vortex mixed and then centrifuged at 10 000g for 10 minutes. The supernatant was removed and dried in a concentrator (Eppendorf concentrator plus) for 3 hours at room temperature and reconstituted in 50 µl water directly prior to LC-MS/MS analysis.

**Chromatographic conditions and mass-spectrometry detection.** LC-MS/MS analysis was performed on a TSQ Vantage triple quadrupole mass spectrometer coupled with an Accela UHPLC system (Thermo Fisher Scientific, Massachusetts, USA). Chromatographic separation was performed using a Thermo Scientific™ Hypersil GOLD™ HPLC column with a particle size 1.9 µm, 100 mm length and 2.1 mm diameter maintained at 25 °C. 10 µl of sample was injected onto the column. The mobile phase consisted of ACN with 0.1% formic acid as the organic component (B) and water with 0.1% formic acid as the aqueous phase (A). The system was maintained in 8% buffer B at a flow rate of 0.3 ml min<sup>-1</sup>. Samples were maintained at 4 °C prior to analysis.

Tofacitinib and tofacitinib-d3 were detected using heated electrospray ionisation in positive ion mode using the following

selected reaction monitoring (SRM) transitions: 313.0 > 173.06 for tofacitinib and 316.3 > 176.1 for tofacitinib-d3. The mass spectrometer settings were optimised as follows: spray voltage 5000 V, capillary temperature 369 °C, vaporiser temperature 353 °C and collision energy 29 eV. Argon was used as collision gas. Quantitation was calculated using the peak-area ratio of the analyte to internal standard using LCQuan software (Thermo Fisher Scientific, MA, USA).

**Method validation.** Validation of the assay was tested as adapted from European Medicines Agency guidelines on Bio-analytical Validation.<sup>13</sup> Specifically, we determined the lower limit of quantification (LLOQ), carryover, accuracy, linearity, precision, recovery and stability of the assay.

The LLOQ was defined as the lowest standard with a signal to noise ratio ≥ 5 and a signal for tofacitinib at least 5 times that of blank serum samples. Carryover was calculated as the percentage of residual signal present in a blank sample following an injection of 1000 ng ml<sup>-1</sup> tofacitinib. 50 µl of serum was spiked with tofacitinib/tofacitinib-d3 to achieve final concentrations of 0.01 ng ml<sup>-1</sup>, 0.05 ng ml<sup>-1</sup>, 0.1 ng ml<sup>-1</sup>, 0.5 ng ml<sup>-1</sup>, 1 ng ml<sup>-1</sup>, 5 ng ml<sup>-1</sup>, 10 ng ml<sup>-1</sup>, 50 ng ml<sup>-1</sup>, 100 ng ml<sup>-1</sup>, 500 ng ml<sup>-1</sup> and 1000 ng ml<sup>-1</sup>. Tofacitinib-d3 remained constant at 50 ng ml<sup>-1</sup>. In each run blank serum samples were also analysed. Samples were prepared in triplicate.

Linearity was tested in independent triplicate samples. 50 µl of serum was spiked with tofacitinib/tofacitinib-d3 to achieve final concentrations of 0.01 ng ml<sup>-1</sup>, 0.05 ng ml<sup>-1</sup>, 0.1 ng ml<sup>-1</sup>, 0.5 ng ml<sup>-1</sup>, 1 ng ml<sup>-1</sup>, 5 ng ml<sup>-1</sup>, 10 ng ml<sup>-1</sup>, 50 ng ml<sup>-1</sup> and 100 ng ml<sup>-1</sup>. Tofacitinib-d3 remained constant at 50 ng ml<sup>-1</sup>.

Accuracy and precision (within-run) were tested on 5 samples at final concentrations of 0.1 ng ml<sup>-1</sup>, 0.25 ng ml<sup>-1</sup>, 2.5 ng ml<sup>-1</sup> and 50 ng ml<sup>-1</sup>. Accuracy and precision (between-run) were evaluated on samples at final concentrations of 0.1 ng ml<sup>-1</sup>, 0.25 ng ml<sup>-1</sup>, 2.5 ng ml<sup>-1</sup> and 50 ng ml<sup>-1</sup> across 3 runs with a fresh standard curve prepared for each run. Accuracy of the assay is reported as the calculated concentration of each sample as a percentage of the nominal concentration.

**Proof of concept study.** To investigate the ability of the assay to detect adherence, a random selection of serum samples (*n* = 10) of patients prescribed tofacitinib who self-report adherent behaviour from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) were analysed (REC reference: 04/Q1403/37). Participants self-reported date and time of tofacitinib ingestion prior to venepuncture. Samples were analysed in triplicate.

## Results and discussion

### Lower limit of quantification and carryover

The LLOQ for tofacitinib was 0.1 ng ml<sup>-1</sup> as this gave a signal to noise ratio of ≥5. Carryover of sample following injection of a 1000 ng ml<sup>-1</sup> tofacitinib was <1% (Fig. 1).

### Linearity

Linearity was assessed using linear least-squared regression analysis and demonstrated excellent concordance (Fig. 2).





Table 2 Tofacitinib recovery results

Expected concentration (ng ml <sup>-1</sup> )	Spiked before extraction mean (ng l <sup>-1</sup> ) (SD)	Spiked post extraction mean (ng l <sup>-1</sup> ) (SD)	Mean tofacitinib recovery (%)
0.1	0.12 (0.02)	0.11 (0.01)	108.55
0.25	0.28 (0.01)	0.25 (0.01)	110.71
0.5	0.52 (0.04)	0.49 (0.04)	106.65
1	0.99 (0.08)	0.89 (0.03)	111.28
2.5	2.61 (0.13)	2.41 (0.16)	108.24
5	5.30 (0.22)	4.82 (0.06)	109.88
10	10.7 (0.75)	9.91 (0.34)	104.66
50	55.21 (3.83)	50.20 (0.82)	109.98
100	108.26 (4.57)	100.39 (0.47)	107.84

Table 3 Results of tofacitinib biochemical adherence testing

Sample ID	Time difference between self-reported tofacitinib ingestion and blood sample (hours)	Mean tofacitinib (ng ml <sup>-1</sup> , n = 3)	CV (%)
49	7.0	26.43	2.82
40	2.8	100.55	5.51
70	3.6	73.23	2.27
68	1.5	150.37	8.09
20	1.5	137.46	9.09
30	1.8	117.85	14.97
33	1.4	90.89	1.18
79	5.4	217.47	11.40
17	2.8	108.43	7.43
37	2.5	335.04	3.48

### Proof of concept study

To demonstrate the potential of the assay to biochemically measure adherence, all 10 BRAGGSS samples of tofacitinib treated RA patients successfully revealed tofacitinib levels above 0.1 ng ml<sup>-1</sup> with CV < 15% (Table 3).

## Conclusions

Adherence to long-term medication is suboptimal and costs the NHS £500 million per year.<sup>16</sup> Non-adherence is a common health behaviour that is difficult to measure. Clinicians are often unaware of medication non-adherence and the development of an objective test of non-adherence is a vital first step so that supportive interventions can be put in place to optimise patient adherence.

We have successfully developed a novel sensitive tofacitinib LC-MS/MS assay with its sensitivity and validation against the EMA guidelines. Furthermore, the ability of the assay to measure circulating tofacitinib has been explored from patient samples and compared with self-reported adherence. Further research to investigate the ability of the assay to detect adherence in a heterogenous population prescribed tofacitinib using a population pharmacokinetic approach is warranted. This assay is appropriate for use in further research studies to establish the sensitivity of the assay for the detection of non-adherence.

## Author contributions

SC formal analysis. KH conceptualization, methodology and data curation. KO methodology. RDU supervision, methodology and resources. AB conceptualization, methodology and data curation. JB conceptualization, methodology, funding acquisition. All authors writing – review & editing.

## Conflicts of interest

Financial support was provided as an Investigator Sponsored Research Grant from Pfizer Limited. JB has received travel/conference fees from UCB, Pfizer and Eli Lilly. AB has received speaker fees, consultancy fees and/or grant funding from Galapagos, Scipher Medicine, Pfizer, Bristol Myers Squibb and Roche-Chugai. KLH has received speaker fees, consultancy fees and/or grant funding from Abbvie, Pfizer and Bristol Myers Squibb.

## Acknowledgements

This work was supported by Versus Arthritis (21754), MRC (MR/K015346/1) and the NIHR Manchester and Leeds BRCs. The views expressed are those of the authors and not necessarily those of the NHS, National Institute for Health research or the Department of Health. The list of BRAGGSS collaborators and affiliations is available in the online supplementary information. AB is an NIHR Senior Investigator.

## Notes and references

- 1 J. A. Hodge, T. T. Kawabata, S. Krishnaswami, J. D. Clark, J. B. Telliez, M. E. Dowty, S. Menon, M. Lamba and S. Zwillich, The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis, *Clin. Exp. Rheumatol.*, 2016, **34**(2), 318–328.
- 2 A. Finckh, M. H. Liang, C. M. van Herckenrode and P. de Pablo, Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis, *Arthritis Rheum.*, 2006, **55**(6), 864–872.
- 3 J. Bluett, C. Morgan, L. Thurston, D. Plant, K. L. Hyrich, A. W. Morgan, A. G. Wilson, J. D. Isaacs, L. Cordingley,



- A. Barton and Braggss, Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort, *Rheumatology*, 2015, **54**(3), 494–499.
- 4 F. Salaffi, M. Di Carlo, S. Farah and M. Carotti, Adherence to subcutaneous anti-TNF $\alpha$  agents in patients with rheumatoid arthritis is largely influenced by pain and skin sensations at the injection site, *Int. J. Rheum. Dis.*, 2020, **23**(4), 480–487.
- 5 R. Alten, K. Kruger, J. Rellecke, J. Schiffner-Rohe, O. Behmer, G. Schiffhorst and H. D. Nolting, Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach, *Patient Preference and Adherence*, 2016, **10**, 2217–2228.
- 6 V. Strand, J. M. Kremer, D. Gruben, S. Krishnaswami, S. H. Zwillich and G. V. Wallenstein, Tofacitinib in Combination with Conventional Disease-Modifying Antirheumatic Drugs in Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase III Randomized Controlled Trial, *Arthritis Care Res.*, 2017, **69**(4), 592–598.
- 7 V. Strand, R. F. van Vollenhoven, E. B. Lee, R. Fleischmann, S. H. Zwillich, D. Gruben, T. Koncz, B. Wilkinson and G. Wallenstein, Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis, *Rheumatology*, 2016, **55**(6), 1031–1041.
- 8 R. Fleischmann, E. Mysler, S. Hall, A. J. Kivitz, R. J. Moots, Z. Luo, R. DeMasi, K. Soma, R. Zhang, L. Takiya, S. Tatulych, C. Mojcik, S. Krishnaswami, S. Menon, J. S. Smolen and O. S. investigators, Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial, *Lancet*, 2017, **390**(10093), 457–468.
- 9 I. Khilfeh, E. Guyette, J. Watkins, D. Danielson, D. Gross and K. Yeung, Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study, *Journal of Managed Care and Specialty Pharmacy*, 2019, **25**(4), 461–467.
- 10 J. Harnett, R. Gerber, D. Gruben, A. S. Koenig and C. Chen, Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database, *Journal of Managed Care and Specialty Pharmacy*, 2016, **22**(12), 1457–1471.
- 11 T. Smith, J. Harnett, D. Gruben, C. Chen, E. Agarwal and J. Woolcott, Real-world experience with tofacitinib versus adalimumab and etanercept in biologic-naïve patients with RA previously treated with methotrexate: data from a US administrative healthcare insurance claims database, *Arthritis Rheumatol.*, 2017, vol. 69, (suppl. 10).
- 12 M. Suzuki, S. Tse, M. Hirai and Y. Kurebayashi, Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in Japanese, *Kobe J. Med. Sci.*, 2017, **62**(6), E150–E161.
- 13 European Medicines Agency, *Guideline on bioanalytical method validation*, 2011, cited 21/02/2018, available from: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2011/08/WC500109686.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf).
- 14 R. Zeng, H. Gong, Y. Li, Y. Li, W. Lin, D. Tang and D. Knopp, CRISPR-Cas12a-Derived Photoelectrochemical Biosensor for Point-of-Care Diagnosis of Nucleic Acid, *Anal. Chem.*, 2022, **94**(20), 7442–7448.
- 15 Z. Yu, H. Gong, Y. Li, J. Xu, J. Zhang, Y. Zeng, X. Liu and D. Tang, Chemiluminescence-Derived Self-Powered Photoelectrochemical Immunoassay for Detecting a Low-Abundance Disease-Related Protein, *Anal. Chem.*, 2021, **93**(39), 13389–13397.
- 16 L. Taylor, Drug non-adherence “costing NHS £500M+ a year”, *PharmaTimes online*, 2013, available from: [https://www.pharmatimes.com/news/drug\\_non-adherence\\_costing\\_nhs\\_500m\\_a\\_year\\_1004468](https://www.pharmatimes.com/news/drug_non-adherence_costing_nhs_500m_a_year_1004468).

